Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

620 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues.
Pusceddu S, Vernieri C, Di Maio M, Marconcini R, Spada F, Massironi S, Ibrahim T, Brizzi MP, Campana D, Faggiano A, Giuffrida D, Rinzivillo M, Cingarlini S, Aroldi F, Antonuzzo L, Berardi R, Catena L, De Divitiis C, Ermacora P, Perfetti V, Fontana A, Razzore P, Carnaghi C, Davì MV, Cauchi C, Duro M, Ricci S, Fazio N, Cavalcoli F, Bongiovanni A, La Salvia A, Brighi N, Colao A, Puliafito I, Panzuto F, Ortolani S, Zaniboni A, Di Costanzo F, Torniai M, Bajetta E, Tafuto S, Garattini SK, Femia D, Prinzi N, Concas L, Lo Russo G, Milione M, Giacomelli L, Buzzoni R, Delle Fave G, Mazzaferro V, de Braud F. Pusceddu S, et al. Among authors: berardi r. Gastroenterology. 2018 Aug;155(2):479-489.e7. doi: 10.1053/j.gastro.2018.04.010. Epub 2018 Apr 13. Gastroenterology. 2018. PMID: 29655834 Free article.
Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy.
Scartozzi M, Bearzi I, Pierantoni C, Mandolesi A, Loupakis F, Zaniboni A, Catalano V, Quadri A, Zorzi F, Berardi R, Biscotti T, Labianca R, Falcone A, Cascinu S. Scartozzi M, et al. Among authors: berardi r. J Clin Oncol. 2007 Sep 1;25(25):3930-5. doi: 10.1200/JCO.2007.11.5022. J Clin Oncol. 2007. PMID: 17761976
Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial.
Cascinu S, Berardi R, Labianca R, Siena S, Falcone A, Aitini E, Barni S, Di Costanzo F, Dapretto E, Tonini G, Pierantoni C, Artale S, Rota S, Floriani I, Scartozzi M, Zaniboni A; Italian Group for the Study of Digestive Tract Cancer (GISCAD). Cascinu S, et al. Among authors: berardi r. Lancet Oncol. 2008 Jan;9(1):39-44. doi: 10.1016/S1470-2045(07)70383-2. Lancet Oncol. 2008. PMID: 18077217 Clinical Trial.
Treatment trends in metastatic pancreatic cancer patients: Is it time to change?
Reni M, Pasetto LM, Passardi A, Milella M, Mambrini A, Cereda S, Aprile G, Tronconi MC, Berardi R, Cordio S, Sartori N, Rognone A, Pederzoli P, Falconi M. Reni M, et al. Among authors: berardi r. Dig Liver Dis. 2011 Mar;43(3):225-30. doi: 10.1016/j.dld.2010.09.010. Epub 2010 Nov 2. Dig Liver Dis. 2011. PMID: 21044873
The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab.
Scartozzi M, Mandolesi A, Giampieri R, Bittoni A, Pierantoni C, Zaniboni A, Galizia E, Giustini L, Silva RR, Bisonni R, Berardi R, Biscotti T, Biagetti S, Bearzi I, Cascinu S. Scartozzi M, et al. Among authors: berardi r. Oncologist. 2011;16(1):53-60. doi: 10.1634/theoncologist.2010-0119. Epub 2011 Jan 6. Oncologist. 2011. PMID: 21212430 Free PMC article.
Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study.
Cascinu S, Berardi R, Sobrero A, Bidoli P, Labianca R, Siena S, Ferrari D, Barni S, Aitini E, Zagonel V, Caprioni F, Villa F, Mosconi S, Faloppi L, Tonini G, Boni C, Conte P, Di Costanzo F, Cinquini M; Italian Group for the Study of Digestive Tract Cancer (GISCAD). Cascinu S, et al. Among authors: berardi r. Dig Liver Dis. 2014 Feb;46(2):182-6. doi: 10.1016/j.dld.2013.09.020. Epub 2013 Nov 2. Dig Liver Dis. 2014. PMID: 24189171 Clinical Trial.
Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey.
Santini D, Procopio G, Porta C, Ibrahim T, Barni S, Mazzara C, Fontana A, Berruti A, Berardi R, Vincenzi B, Ortega C, Ottaviani D, Carteni G, Lanzetta G, Virzì V, Santoni M, Silvestris N, Satolli MA, Collovà E, Russo A, Badalamenti G, Fedeli SL, Tanca FM, Adamo V, Maiello E, Sabbatini R, Felici A, Cinieri S, Tonini G, Bracarda S. Santini D, et al. Among authors: berardi r. PLoS One. 2013 Dec 30;8(12):e83026. doi: 10.1371/journal.pone.0083026. eCollection 2013. PLoS One. 2013. PMID: 24386138 Free PMC article.
Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?
Santoni M, Conti A, Procopio G, Porta C, Ibrahim T, Barni S, Guida FM, Fontana A, Berruti A, Berardi R, Massari F, Vincenzi B, Ortega C, Ottaviani D, Carteni G, Lanzetta G, De Lisi D, Silvestris N, Satolli MA, Collovà E, Russo A, Badalamenti G, Luzi Fedeli S, Tanca FM, Adamo V, Maiello E, Sabbatini R, Felici A, Cinieri S, Montironi R, Bracarda S, Tonini G, Cascinu S, Santini D. Santoni M, et al. Among authors: berardi r. J Exp Clin Cancer Res. 2015 Feb 5;34(1):10. doi: 10.1186/s13046-015-0122-0. J Exp Clin Cancer Res. 2015. PMID: 25651794 Free PMC article.
620 results